| abstract |
The present specification relates to treating muscle fatigue related disorders in a patient using a therapeutically effective amount of an antagonist of Fbxo40 that decreases the expression, level or activity of Fbxo40. Fbxo40 antagonists increase muscle mass or prevent, limit or decrease muscle mass loss in patients. The Fbxo40 antagonist can be a low molecular weight (LMW) compound, protein, antibody or inhibitory nucleic acid, eg, siRNA. The present description also relates to methods for screening for antagonists of Fbxo40 and methods for diagnosing or monitoring the level of muscle mass maintenance, loss or increase. |